Clinical Trials Logo

Leukemia, Lymphoid clinical trials

View clinical trials related to Leukemia, Lymphoid.

Filter by:

NCT ID: NCT06034561 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia, in Relapse

Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia

Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

This is a interventional phase II study aiming to examine the complete response rate of a bortezomib-based salvage regimen in adults with refractory or relapsed acute lymphoblastic leukemia (ALL), seeking to compare outcomes with the available literature and with our historical data on relapsed/refractory ALL.

NCT ID: NCT06027957 Recruiting - Clinical trials for B-Cell Acute Lymphoblastic Leukemia

CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia

Start date: August 2, 2023
Phase: Phase 1
Study type: Interventional

- Brief Summary: Cluster of differentiation 19 (CD19) is expressed on B cells. CD19+ tumor cells in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia can be targeted using T cells expressing CD19-specific chimeric antigen receptor (CAR). - Objective: This study aims to evaluate the safety and efficacy of single-dose anti-CD19 CAR T-cell therapy in the treatment of relapsed/refractory CD19+ non-Hodgkin lymphoma and acute lymphoblastic leukemia. - Eligibility: People aged 1 to 60 years with relapsed/refractory CD19+ non-Hodgkin lymphoma and acute lymphoblastic leukemia. - Design: Phase 1 clinical trial, uncontrolled, single dose of CD19 CAR T-cells.

NCT ID: NCT06025682 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO

INO-FIRST
Start date: April 4, 2024
Phase:
Study type: Observational

The goal of this observational study is to learn about infectious complications in patients affected by B-cell acute lymphoblastic leukemia treated with inotuzumab-ozogamicin (INO). The main question it aims to answer is: • incidence of infectious complications (bacterial, fungal, viral) in patients receiving inotuzumab ozogamicin up to 60 days after the end of treatment

NCT ID: NCT06009107 Not yet recruiting - Clinical trials for B-cell Acute Lymphoblastic Leukemia

A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)

B-ALL
Start date: August 31, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multi-center, phase I/II trial to evaluate the safety and efficacy of HY004 treatment in Adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL).

NCT ID: NCT06001385 Recruiting - Lymphoma Clinical Trials

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

OPTIMIZE
Start date: December 8, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question[s] it aims to answer are: - Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant? - Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard dose of PTCy?

NCT ID: NCT05999877 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

PICAROS - Acalabrutinib RWE on 1L CLL in Spain

PICAROS
Start date: July 11, 2023
Phase:
Study type: Observational

This is a multicenter non-interventional study (NIS) on patients with CLL who have been treated with acalabrutinib for the first time within the year before the first site initiation visit in Spain

NCT ID: NCT05993949 Recruiting - Clinical trials for Lymphoblastic Leukemia

Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia

Start date: October 2, 2023
Phase: Phase 1
Study type: Interventional

To assess the feasibility of oral dasatinib pulses (3 consecutive days per week) during the first month following infusion of brexucabtagene autoleucel (Tecartus) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

NCT ID: NCT05991973 Recruiting - Clinical trials for T Lymphoblastic Leukemia/Lymphoma

Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas

Start date: July 15, 2023
Phase: Phase 2
Study type: Interventional

Clinical Study on the Safety and Effectiveness of low-dose chidamide maintenance therapy after allogeneic hematopoietic stem cell transplantation for T-cell acute lymphoblastic leukemia or T-cell lymphomas.

NCT ID: NCT05971251 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia

Start date: December 18, 2023
Phase: Phase 1
Study type: Interventional

Study is a phase I study to determine the maximum tolerated dose of adding Loncastuximab Tesirine to Aclabrutinib in the treatment of chronic lymphocytic leukemia.

NCT ID: NCT05963971 Recruiting - Obesity Clinical Trials

A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors

PEDALL
Start date: June 23, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is determine the effectiveness of a six-month virtually-delivered dietary education intervention (PEDALL) on the prevention of overweight and obesity (OW/OB) during maintenance chemotherapy in children and adolescents with acute lymphoblastic leukemia (ALL).